Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masahiro Azuma

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Expert Opinion on Therapeutic Targets|February 19, 2013
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancerTsukasa Seya, Masahiro Azuma, Misako Matsumoto
Journal of Experimental & Clinical Cancer Research : CR|September 14, 2016
Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapyYohei Takeda, Masahiro Azuma, Misako Matsumoto, et al.
Methods in Enzymology|January 1, 2014
Assessment of the Toll-like receptor 3 pathway in endosomal signalingMisako Matsumoto, Kenji Funami, Megumi Tatematsu, et al.
Journal of Innate Immunity|April 2, 2011
Natural killer cell activation secondary to innate pattern sensingTsukasa Seya, Jun Kasamatsu, Masahiro Azuma, et al.
Oncoimmunology|August 31, 2012
Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cellsMasahiro Azuma, Takashi Ebihara, Hiroyuki Oshiumi, et al.
Biochemical and Biophysical Research Communications|January 18, 2015
Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signalingAkira Maruyama, Hiroaki Shime, Yohei Takeda, et al.
Frontiers in Immunology|March 30, 2018
Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a <i>Mycoplasma fermentans</i> LipopeptideYohei Takeda, Masahiro Azuma, Kenji Funami, et al.
Oncoimmunology|November 20, 2012
TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosisTsukasa Seya, Hiroaki Shime, Hiromi Takaki, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|March 13, 2018
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapyTsukasa Seya, Yohei Takeda, Ken Takashima, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 18, 2014
IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infectionMasaaki Okamoto, Hiroyuki Oshiumi, Masahiro Azuma, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Expert Opinion on Therapeutic Targets|February 19, 2013
Targeting TLR3 with no RIG-I/MDA5 activation is effective in immunotherapy for cancerTsukasa Seya, Masahiro Azuma, Misako Matsumoto
Journal of Experimental & Clinical Cancer Research : CR|September 14, 2016
Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapyYohei Takeda, Masahiro Azuma, Misako Matsumoto, et al.
Methods in Enzymology|January 1, 2014
Assessment of the Toll-like receptor 3 pathway in endosomal signalingMisako Matsumoto, Kenji Funami, Megumi Tatematsu, et al.
Journal of Innate Immunity|April 2, 2011
Natural killer cell activation secondary to innate pattern sensingTsukasa Seya, Jun Kasamatsu, Masahiro Azuma, et al.
Oncoimmunology|August 31, 2012
Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cellsMasahiro Azuma, Takashi Ebihara, Hiroyuki Oshiumi, et al.
Biochemical and Biophysical Research Communications|January 18, 2015
Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signalingAkira Maruyama, Hiroaki Shime, Yohei Takeda, et al.
Frontiers in Immunology|March 30, 2018
Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a <i>Mycoplasma fermentans</i> LipopeptideYohei Takeda, Masahiro Azuma, Kenji Funami, et al.
Oncoimmunology|November 20, 2012
TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosisTsukasa Seya, Hiroaki Shime, Hiromi Takaki, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|March 13, 2018
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapyTsukasa Seya, Yohei Takeda, Ken Takashima, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 18, 2014
IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infectionMasaaki Okamoto, Hiroyuki Oshiumi, Masahiro Azuma, et al.
Pageof 3